JP2019501130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501130A5 JP2019501130A5 JP2018526565A JP2018526565A JP2019501130A5 JP 2019501130 A5 JP2019501130 A5 JP 2019501130A5 JP 2018526565 A JP2018526565 A JP 2018526565A JP 2018526565 A JP2018526565 A JP 2018526565A JP 2019501130 A5 JP2019501130 A5 JP 2019501130A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 125000000304 alkynyl group Chemical group 0.000 claims 12
- 102000003800 Selectins Human genes 0.000 claims 7
- 108090000184 Selectins Proteins 0.000 claims 7
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims 1
- 208000012634 Venoocclusive liver disease Diseases 0.000 claims 1
- SVEKJHBWJWHXKV-UHFFFAOYSA-N benzylsulfamic acid Chemical compound OS(=O)(=O)NCC1=CC=CC=C1 SVEKJHBWJWHXKV-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000017455 cell-cell adhesion Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 208000018645 hepatic veno-occlusive disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 0 *c1c2C(NCc3ccccc3)=CC=*=Cc2cc(S(O)(=O)=O)c1 Chemical compound *c1c2C(NCc3ccccc3)=CC=*=Cc2cc(S(O)(=O)=O)c1 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262155P | 2015-12-02 | 2015-12-02 | |
| US62/262,155 | 2015-12-02 | ||
| PCT/US2016/064189 WO2017095904A1 (en) | 2015-12-02 | 2016-11-30 | Heterobifunctional pan-selectin antagonists having a triazole linker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019501130A JP2019501130A (ja) | 2019-01-17 |
| JP2019501130A5 true JP2019501130A5 (enExample) | 2020-01-09 |
Family
ID=57681725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526565A Pending JP2019501130A (ja) | 2015-12-02 | 2016-11-30 | トリアゾールリンカーを有するヘテロ二官能性の汎セレクチン拮抗剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200171005A9 (enExample) |
| EP (1) | EP3383882A1 (enExample) |
| JP (1) | JP2019501130A (enExample) |
| CA (1) | CA2950088A1 (enExample) |
| WO (1) | WO2017095904A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519181B2 (en) | 2014-12-03 | 2019-12-31 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
| WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
| JP2019524791A (ja) | 2016-08-08 | 2019-09-05 | グリコミメティクス， インコーポレイテッド | Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ |
| CN117298287A (zh) | 2016-10-07 | 2023-12-29 | 糖模拟物有限公司 | 高效的多聚体e-选择蛋白拮抗剂 |
| WO2018169853A1 (en) | 2017-03-15 | 2018-09-20 | Glycomimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
| JP7275131B2 (ja) | 2017-11-30 | 2023-05-17 | グリコミメティクス， インコーポレイテッド | 骨髄浸潤リンパ球を動員する方法、およびその使用 |
| WO2019133878A1 (en) * | 2017-12-29 | 2019-07-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
| WO2019173229A1 (en) | 2018-03-05 | 2019-09-12 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| US20220220144A1 (en) * | 2019-04-24 | 2022-07-14 | Glycomimetics, Inc. | Multimeric pan-selectin antagonists |
| AU2020334987A1 (en) * | 2019-08-20 | 2022-03-31 | Glycomimetics, Inc. | Process for preparing an E-selectin inhibitor intermediate |
| WO2021195465A1 (en) | 2020-03-27 | 2021-09-30 | Magnani John L | Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin |
| JP2023527411A (ja) | 2020-05-31 | 2023-06-28 | グリコミメティクス， インコーポレイテッド | がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法 |
| AU2021292458A1 (en) | 2020-06-14 | 2023-01-19 | GlycoMimetics | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting |
| US20240269157A1 (en) | 2021-08-03 | 2024-08-15 | Glycomimetics, Inc. | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006515306A (ja) * | 2002-12-20 | 2006-05-25 | グリコミメティクス， インコーポレイテッド | Ｐｓｅｕｄｏｍｏｎａｓ細菌感染の処置のためのオリゴ糖およびその結合体 |
| US7728117B2 (en) * | 2005-09-02 | 2010-06-01 | Glycomimetics, Inc. | Heterobifunctional pan-selectin inhibitors |
| WO2009126556A1 (en) * | 2008-04-08 | 2009-10-15 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
| US8921328B2 (en) * | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
-
2016
- 2016-11-30 JP JP2018526565A patent/JP2019501130A/ja active Pending
- 2016-11-30 US US15/781,072 patent/US20200171005A9/en not_active Abandoned
- 2016-11-30 WO PCT/US2016/064189 patent/WO2017095904A1/en not_active Ceased
- 2016-11-30 EP EP16820045.9A patent/EP3383882A1/en not_active Withdrawn
- 2016-11-30 CA CA2950088A patent/CA2950088A1/en not_active Abandoned